Mariusz Korkosz

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 390 citations · Full text

Rheumatoid Disorder, Rheumatology, Spirit-p2 Phase 3 +12

MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

Frank Behrens, Paul P. Tak, Mikkel Østergaard et al. · Annals of the Rheumatic Diseases · 2014 · 151 citations · Full text

A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

Gerd R Burmester, Iain B. McInnes, Joel M. Kremer et al. · Annals of the Rheumatic Diseases · 2017 · 124 citations · Full text

Differential Associations of Inflammatory and Endothelial Biomarkers with Disease Activity in Rheumatoid Arthritis of Short Duration

Ewa Klimek, Anna Skalska, Beata Kwaśny-Krochin et al. · Mediators of Inflammation · 2014 · 65 citations · Full text

Hand radiographs preprocessing, image representation in the finger regions and joint space width measurements for image interpretation

Andrzej Bielecki, Mariusz Korkosz, Bartosz Zieliński · Pattern Recognition · 2008 · 50 citations · Full text

Image Analysis, Kinesiology, Medical Imaging +11